Do you think that your American experience might be different from that of a person of color? (Non-violent) protesting is the right of every American. It's what separates us from the North Koreans.
day 4 of 10. And what a day!! Great volume. IMO this was not just the result of today's PR, but an acknowledgement of all the positives that have been happening the last couple months.
I have trouble believing that with all the experience they have coming on board, nobody has raised the issue. Which makes me think it's not an issue. But Leo is usually pretty responsive, so why not ASK HIM?
Don't forget, he who LOLOLOLs last, often LOLOLOLs loudest.
Not sure what more you could want from a company with $50 million market cap. They have $40 million in cash, partnerships with three big pharmas, and a diverse pipeline. I'm not here to hit singles. I want homeruns which also means striking out from time to time, but I like the odds here.
I don't own any of those. Just some ctix that I'm sticking with against my better judgement and a good chunk of blrx which I still like despite the share price. $50 million MC, $40 million in the bank plus collaborations with actual BP companies.
"don't need a partner"? you're kidding, right? this company needs a partner DESPERATELY! why is BP not fighting among themselves to fund these trials? the answer is the simplest one - the potential ain't what we thought it was.
Interesting presentation given yesterday at R&R conference. Linked to on company website - can listen to it and view slides. Lots going on for a little company. Got to get over $1 for 10 days and eliminate that de-listing (or RS) concern. Is this company's potential that different from where cpxx was when they were acquired for 1.5B??!
This obsession you have with toxlcdumper (who doesn't even post here anymore and probably doesn't even own shares) is odd. Go find a hobby.
I wonder if this is a catch-22 situation. People don't want to buy with the threat of delisting for being under $1, but it won't get over $1 without people buying. Results looked promising to me. Pair that with solid cash position and moving on from a poor ceo, seems like a decent place to put a bet down.
Found this article on an israeli website:
Drug development company BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) today announced it had signed an agreement with pharmaceutical powerhouse Genentech of the Roche Group for cooperation in a clinical trial for testing a combination of the two companies' drugs in the treatment of a number of types of solid-tumor cancer and AML leukemia. BioLIneRX's cancer drug, BL-8040, is currently in simultaneous Phase II trials for treatment of AML and in combination with Merck's KEYTRUDA, which is already on the market for treatment of several types of cancer. Following the announcement, the BioLineRX share price rose 1%, lifting the company's market cap to NIS 187 million.
Under the agreement with Genentech, BioLineRX's product will be tested in combination with Genentech's Atezolizumab (brand name Tecentriq), part of a family of cancer drugs that induce the immune system to combat the disease (autoimmune drugs). Genentech's drug was approved for marketing last May for treatment of prostate cancer, and is also being tested independently and in different combinations for other types of cancer.
In the first stage, the safety profile of the combination of the two drugs and the drug's behavior in the patients' bodies will be tested, and the companies will look for hints about the effectiveness of the drug. Genentech will finance these trials, while BioLineRX will finance a trial conducted for the combination of the two drugs in the treatment of AML.
BL-8040 directly kills cancer cells
The trials with be without a control group, as is usually the case in cancer trials at this stage, but will take place at multiple medical centers. If one of these trials produces successful results, each of the parties will have the option to continue the cooperatio
Good stuff happening here.
Full set of data from Phase 2a study for BL-8040 in r/r AML to be presented at the Society of Hematologic Oncology (SOHO) annual meeting, September 7-10, 2016, in Houston, Texas
Come on, I know you Trump supporters are gullible but that's too much. The tone and wording of that fluff was exactly like Leo's fluff. Do you think that Menon's "quotes" in PRs are actually his words too? I'd bet Leo put that nonsense out and Dr B told him to knock it off.
You'd rather yet another fluffy PR that tells us nothing? This is a great PR and a great hire, Leo is putting an actual company together. Read between the lines - are quality people coming on board for poor drug candidates? I'm guessing that Dr B told Leo to cut out the fluff after the last PR talking about results from one person. Glad that Leo listened.
Today's action looks like a pump and dump to me. It was getting pushed on stocktwits today. Be nice to see follow through rest of week, but I think it's just a bunch of day traders.